Medpace Holdings, Inc. (MEDP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 926 | 1,142 | 1,460 | 1,886 | 2,109 | 2,530 | 2,782 | 2,850 |
| Operating profit | $m | 535 | 583 | ||||||
| Net profit | $m | 145 | 182 | 245 | 283 | 404 | 451 | 492 | 519 |
| EPS reported | $ | 15.28 | 17.07 | ||||||
| Operating cashflow per share | $ | 24.73 | 26.59 | ||||||
| Capex per share | $ | 1.09 | 0.68 | ||||||
| FCF per share | $ | 23.64 | 25.91 | ||||||
| Free cash flow | $m | 682 | 734 | ||||||
| Net debt | $m | -360 | -503 | ||||||
| Book value equity | $m | 459 | 434 | ||||||
| Book value per share | $ | 15.55 | 15.09 | ||||||
| Number of shares | m | 29.53 | 28.76 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 36.76 | 36.26 | ||||||
| P/B LTM | x | 35.29 | 37.34 | ||||||
| P/S LTM | x | 6.40 | 5.82 | ||||||
| P/FCF LTM | x | 23.76 | 22.09 | ||||||
| EV/EBITDA LTM | x | 27.97 | 26.50 | ||||||
| EV/Sales LTM | x | 6.31 | 5.67 | ||||||
| Earnings Yield LTM | % | +2.72% | +2.76% | ||||||
| FCF Yield | % | +4.21% | +4.53% | ||||||
| Quality | |||||||||
| ROE | % | +98.27% | +110.15% | ||||||
| ROIC | % | +67.94% | +77.00% | ||||||
| Operating margin | % | +21.14% | +20.97% | ||||||
| Gross margin | % | +30.06% | +28.76% | ||||||
| FCF/Sales | % | +26.95% | +26.36% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +20.98% | +35.15% | ||||||
| Sales Growth YoY | % | +19.97% | +31.92% | ||||||
| Net Income Growth YoY | % | +11.56% | +21.54% | ||||||
| FCF Growth | % | +19.15% | +28.18% | ||||||
| Operating Profit Growth | % | +19.71% | +30.55% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 2.72 | 6.11 | ||||||
| Net Debt/EBITDA | x | -0.43 | -0.64 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.84% | 0.00% | ||||||
| Net debt/Equity | x | -0.78 | -1.16 | ||||||
| Gross debt/equity | x | 0.55 | 0.28 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free